

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
26 June 2025 (26.06.2025)



(10) International Publication Number
WO 2025/137439 A2

(51) International Patent Classification:
C07K 14/495 (2006.01) C12N 5/0783 (2010.01)
C07K 14/71 (2006.01)

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:
PCT/US2024/061267

Published:
— without international search report and to be republished
upon receipt of that report (Rule 48.2(g))
— with sequence listing part of description (Rule 5.2(a))

(22) International Filing Date:
20 December 2024 (20.12.2024)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/612,847 20 December 2023 (20.12.2023) US
63/727,648 03 December 2024 (03.12.2024) US

(71) Applicant: **INTELLIA THERAPEUTICS, INC.**
[US/US]; 40 Erie Street, Cambridge, Massachusetts 02139
(US).

(72) Inventors: **RUDULIER, Christopher**; 40 Erie Street,
Cambridge, Massachusetts 02139 (US). **KORISTKA, Ste-
fanie**; 40 Erie Street, Cambridge, Massachusetts 02139
(US).

(74) Agent: **CHANG, Audrey**; Finnegan, Henderson, Farabow,
Garrett & Dunner, LLP, 901 New York Avenue, NW, Wash-
ington, District of Columbia 20001-4413 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) Title: ENGINEERED T CELLS

(57) Abstract: The present disclosure relates to T cells engineered to comprise a heterologous nucleic acid sequence encoding a dual mutant transforming growth factor beta 1 (dmTGFB1) under control of a promoter sequence and a modification, e.g., knockdown, of an endogenous nucleic acid sequence encoding a TGFB2. In certain embodiments, the cells further comprise a modification, e.g., knockdown, of an endogenous nucleic acid sequence encoding a TNFA; a modification, e.g., knockdown, of an endogenous nucleic acid sequence encoding an IFNG; and insertion of sequence(s) encoding a regulatory T cell promoting molecule, and compositions and uses thereof.

WO 2025/137439 A2